Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Abstracto

Updates in Medication for Sturge-Weber Syndrome: A Mini Review

Pooja Vedmurthy, Anne M. Comi

Sturge-Weber Syndrome is a rare neurovascular disease associated with glaucoma, a port wine birthmark and most commonly, leptomeningeal vascular malformations accompanied by medically refractory epilepsy. Due to the poorer prognosis associated with extensive brain involvement and early onset of seizures, aggressive and early diagnosis and seizure treatment remains a focus. The past decade has produced a base of literature published on studies and trials for interventions to treat and manage these devastating symptoms. This mini-review focuses on a recent multi-centered study of patient reported medications for SWS and on three other recent treatment trials for SWS: the use of the mTOR pathway inhibitors Sirolimus, a trial with Epidiolex (cannabidiol), and presymptomatic treatment of SWS. An overview of treatment progress for patients with SWS, can be beneficial for clinical providers and patients to determine alternative ways of management.